GREENWICH, Conn., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Stardust Power Inc. (NASDAQ: SDST) (“Stardust Power” or the “Company”), an American developer of battery-grade lithium products, today announced that it will release its second quarter 2025 financial results after market close on Wednesday 13 August, 2025. Roshan Pujari, Founder and Chief Executive Officer and Uday Devasper, Chief Financial Officer will host a conference call at 5:30pm ET on Wednesday 13 August, 2025 to discuss the Company’s results. Parti ...

CELEBRATION, Fla., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the second quarter 2025 on Tuesday, August 12, 2025, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day. A link to the audio webcast will be accessible on the “Events ...

Lead investor Bartosz Lipiński, previously Head of Engineering at Solana Labs, will serve as a technical partner CUBE selected to secure storage, staking, and active DeFi execution of Artelo’s digital asset treasury Artelo’s Board approves authorization to expand Company’s SOL treasury management strategy over time SOLANA BEACH, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop ...

MediWound to Report Second Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, August 14 at 8:30 a.m. Eastern Time YAVNE, Israel, August 4, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the second quarter ended June 30, 2025 on Thursday, August 14, 2025. Following the release, MediWound’s management will host a conference call and live webcast a ...

XOMA Royalty adds milestone and royalty economics associated with two partnered assetsEMERYVILLE, Calif. and UTRECHT, The Netherlands and PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) and LAVA Therapeutics N.V. (“LAVA”) (NASDAQ: LVTX) announced today they have entered a definitive share purchase agreement (the “Purchase Agreement” and the transactions set forth in the Purchase Agreement, the “Transactions”) whereby XOMA Royalty will acquire LAVA for ...

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025. MIAMI, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Digi Power X Inc. (“Digi Power X” or the “Company”) (Nasdaq: DGXX / TSXV: DGX), an innovative energy infrastructure company that develops data centers, is pleased to provide unaudited comparative Bitcoin (“BTC”) production results for the month ended July 31, 2025, combined wit ...

- Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to D ...

Kfar Saba, Israel, Aug. 04, 2025 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, today announces preliminary unaudited results for the six months ended June 30, 2025. The Company’s revenues for the six months ended June 30, 2025, are expected to amount to approximately $350,000 compared to $283,000 for the six months ended June 30, ...

Core Insights - Kraig Biocraft Laboratories, Inc. has successfully produced over 250 kilograms of reeled raw recombinant spider silk using automated equipment, setting a new single run record and enhancing quality, yield, and scalability of production [1][4][5] Group 1: Production Improvements - The use of automated reeling equipment allows for fine-tuning the reeling process specifically for spider silk, optimizing fiber consistency and maximizing silk output [3][4] - Automated reeling replaces conventional multi-end systems, significantly improving throughput, labor efficiency, and downstream silk quality [4] Group 2: Strategic Developments - Recent operational momentum includes the expansion of rearing capacity in Asia and the development of new spider silk strains, supporting the mission to bring eco-friendly spider silk fibers to market [5][7] - The compatibility of Kraig Labs' proprietary spider silk cocoons with advanced reeling systems is central to building a vertically integrated production model for spider silk at scale [4][5]

Core Insights - OraSure Technologies, Inc. has appointed Anne Messing as Chief Commercial Officer, bringing over 25 years of experience in the healthcare industry [1][2] - Ms. Messing will oversee Sales, Marketing, Strategic Alliances, and Product Management, aiming to enhance OTI's market leadership and long-term growth [2][4] - The company focuses on improving healthcare access, quality, and value through innovative diagnostic tests and sample management solutions [5] Company Background - OraSure Technologies is a leader in point-of-need and home diagnostic tests, as well as sample management solutions [1][5] - The company, along with its subsidiaries, develops and distributes rapid diagnostic tests and sample collection devices globally [5] - OTI's products are utilized by various sectors, including clinical laboratories, hospitals, and direct consumers [5] Leadership Experience - Prior to joining OTI, Ms. Messing held a significant role at Becton Dickinson, where she led initiatives that exceeded market benchmarks [3] - Her extensive background includes leadership positions at Danaher, Quest Diagnostics, Siemens Healthcare Diagnostics, and ARUP Laboratories [3] - Ms. Messing has a strong foundation in healthcare, starting her career as a certified medical technologist [3] Strategic Vision - The company aims to leverage Ms. Messing's expertise to drive growth and deliver exceptional value to stakeholders [4] - OTI is preparing for impactful product launches as part of its strategic vision for the future [4]